Global Anti-Depressant Drugs Market Expected to Reach $15,983 Million by 2023 - Allied Market Research

PORTLAND, Oregon and PUNE, India, February 16, 2018 /PRNewswire/ --

According to a new report published by Allied Market Research, titled, "Anti-depressant Drugs Market by Depression Disorder, Product, and Geography: Global Opportunity Analysis and Industry Forecast, 2017-2023," the anti-depressant drugs market accounted for $13,755 million in 2016, and is estimated to reach $15,983 million by 2023, registering a CAGR of 2.1% from 2017 to 2023. North America is the highest contributor in the anti-depressant drugs market in 2016; however, Asia-Pacific is expected to witness the highest growth rate during the forecast period.

     (Logo: https://mma.prnewswire.com/media/636519/Allied_Market_Research_Logo.jpg )

Depression affects a person's thoughts, behavior, feelings and sense of well-being and is caused due to biological, genetics, environment, and psychological factors. The symptoms usually include low mood and aversion to physical activity. Depression is more common in women than men. Depression drugs works by fixing chemical imbalance such as lack of serotonin in the brain. Antidepressants helps in the treatment of depression by maintaining balance of various hormones and chemicals in the brain. Although effective treatments are available, many individuals with depression do not have access to treatment or do not take treatment, mainly due to lack of knowledge and social stigma.

Request Sample Report at: https://www.alliedmarketresearch.com/request-sample/2593

The rise in geriatric population, increase in prevalence of depression, and emergence of novel techniques for the development of drugs with fewer side-effects majorly drive the market growth. Furthermore, increase in awareness regarding the disease state and rise in number of people suffering from stress can fuel the growth of the anti-depressant drugs market. However, poor efficacy and safety profiles of the drug, preference for non-pharmacological therapies, and increase in number of patent expiration of antidepressants that lead to weak pipeline are expected to hamper the market growth.

Among the depressive disorder, major depressive disorder is the dominant segment as majority of the people are usually diagnosed with this disorder due to increase in stress levels. However, obsessive compulsive disorder is the fastest growing segment due to increase in the number of drugs for this disorder.

Among the product, selective serotonin reuptake inhibitors dominate the market owing to the large number of prescription of this drugs and large number of clinical trials for these drugs.

For Purchase Enquiry: https://www.alliedmarketresearch.com/purchase-enquiry/2593

In 2016, North America was the dominant revenue contributor, owing to the high prevalence rate of depression, presence of high disposable income, and increase in number of prescriptions for anti-depressants. However, Asia-Pacific is expected to witness the highest CAGR during the analysis period, attributable to presence of populace countries such as India and China leading to large number of people suffering from depression and rise in healthcare expenditure.

KEY FINDINGS OF ANTI-DEPRESSANT DRUGS MARKET STUDY  

• Obsessive compulsive disorder is projected to grow at the highest rate during the analysis period.
• North America dominated global anti-depressant drugs market in 2016, and is projected to continue its dominance in future.
• China is expected to grow highest in Asia-Pacific during the forecast period.
• Major depressive disorder is the largest contributor among the depressive disorder segments in 2016.
• Selective serotonin reuptake inhibitors segment generated the highest revenue, and is expected to continue its dominance in future.

The key players operating in the global anti-depressant drugs market include Alkermes Plc, Allergan Plc, Bristol Myers Squibb Co., Eli Lilly and Co., GlaxoSmithKline Plc, H. Lundbeck, Merck & Co., Inc., Pfizer Inc., Teva Pharmaceutical Industries Ltd., and Takeda Pharmaceutical Co. Ltd.

Other prominent players in the value chain include Opko Health, Intra-Cellular Therapies, Janssen Pharmaceuticals, Lupin, Abbott Laboratories, Novartis, Forest Laboratories, and AstraZeneca.

Ask for discount before buying: https://www.alliedmarketresearch.com/get-discount/2593

About Us: 

Allied Market Research (AMR) is a full-service market research and business-consulting wing of Allied Analytics LLP based in Portland, Oregon. Allied Market Research provides global enterprises as well as medium and small businesses with unmatched quality of "Market Research Reports" and "Business Intelligence Solutions." AMR has a targeted view to provide business insights and consulting to assist its clients to make strategic business decisions and achieve sustainable growth in their respective market domain.

We are in professional corporate relations with various companies and this helps us in digging out market data that helps us generate accurate research data tables and confirms utmost accuracy in our market forecasting. Each and every data presented in the reports published by us is extracted through primary interviews with top officials from leading companies of domain concerned. Our secondary data procurement methodology includes deep online and offline research and discussion with knowledgeable professionals and analysts in the industry.

Contact:
Shriram Dighe
5933 NE Win Sivers Drive
#205, Portland, OR 97220
United States
Toll Free: +1-800-792-5285
UK: +44-845-528-1300
Hong Kong: +852-301-84916
India (Pune): +91-20-66346060
Fax: +1?855?550-5975
[email protected]

Web: https://www.alliedmarketresearch.com

SOURCE Allied Market Research